-
December 28, 2021 Ketamine Rapidly Reduces Depression, According to ‘Most Comprehensive Review’ of Evidence — But Patient Experiences Suggest More ApplicationsPsychedelic Spotlight speaks to a Field Trip Health patient and a psychotherapist, whose experiences suggest...
-
December 27, 2021 Can Psychedelics Treat Alzheimer’s Disease?Since substances such as LSD and psilocybin have powerful anti-inflammatory properties, researchers argue that the...
-
December 24, 2021 Psychedelic Business Spotlight – December 24This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences...
-
December 23, 2021 FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating DisorderThe pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9...
-
December 20, 2021 Why Psychedelic Research May Bring the Next Big Breakthrough in Dementia Treatment"Psychedelics are well-observed to basically rewire the brain," says Return Health CEO Dr. James Kuo,...
-
December 17, 2021 How Spider-Man Helped Richard Nixon Push the War on Drugs in the 1970sLong before this Marvel superhero joined The Avengers, he was recruited by Richard Nixon's anti-drug...
-
December 17, 2021 Psychedelic Business Spotlight – December 17This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints...
-
December 14, 2021 Understanding HPPD to Prioritize Harm Reduction of a Very Real Psychedelic Risk“HPPD is precisely the kind of risk that could fall through the cracks," says journalist...
-
December 13, 2021 Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic EffectChief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could...
-
December 10, 2021 Psychedelic Business Spotlight – December 10This week in psychedelic business news: Wesana Health files a new patent, Silo Pharma is...
